APA (7th ed.) Citation

Døssing, R. H., Hesselberg, E., Clausen, A. B., Luczak, A. A., Presti, M., Svane, I. M., . . . Ellebaek, E. (2026). Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200]. European Journal of Cancer, 242, N.PAG. https://doi.org/10.1016/j.ejca.2026.116780

Chicago Style (17th ed.) Citation

Døssing, Rasmus Haunstrup, et al. "Corrigendum to "Discontinuation of BRAF/MEK Inhibitor Therapy After Long-lasting Response: Clinical Outcomes in Advanced Melanoma" [Eur J Cancer 234 (2026) 116200]." European Journal of Cancer 242 (2026): N.PAG. https://doi.org/10.1016/j.ejca.2026.116780.

MLA (9th ed.) Citation

Døssing, Rasmus Haunstrup, et al. "Corrigendum to "Discontinuation of BRAF/MEK Inhibitor Therapy After Long-lasting Response: Clinical Outcomes in Advanced Melanoma" [Eur J Cancer 234 (2026) 116200]." European Journal of Cancer, vol. 242, 2026, p. N.PAG, https://doi.org/10.1016/j.ejca.2026.116780.